BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16965265)

  • 1. Design and characterization of a platelet-targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency.
    Yan HL; Sun SH; Wang WT; Ding FX; Mei Q; Xue G
    Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):115-25. PubMed ID: 16965265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential.
    Zhang L; Wang J; Yu M; Ru B
    Mol Genet Metab; 2004 Aug; 82(4):304-11. PubMed ID: 15308128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
    J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide.
    Ding FX; Yan HL; Lu YM; Xue G; Mei Q; Huang JJ; Zhao ZY; Wang YZ; Sun SH
    J Biotechnol; 2006 Nov; 126(3):394-405. PubMed ID: 16797768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: an improved fibrinolytic agent targeted to phospholipid-containing thrombi.
    Tanaka K; Einaga K; Tsuchiyama H; Tait JF; Fujikawa K
    Biochemistry; 1996 Jan; 35(3):922-9. PubMed ID: 8547274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
    Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
    J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
    Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
    Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
    Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
    Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction, expression, and characterization of a recombinant annexin B1-low molecular weight urokinase chimera in Escherichia coli.
    Yan HL; Wang WT; He Y; Zhao ZY; Gao YJ; Zhang Y; Sun SH
    Acta Biochim Biophys Sin (Shanghai); 2004 Mar; 36(3):184-90. PubMed ID: 15202502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
    Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
    Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase.
    Jiao J; Yu M; Ru B
    Biochimie; 2001; 83(11-12):1049-55. PubMed ID: 11879733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preparation of thrombus-targeted urokinase liposomes and its thrombolytic effect in model rats].
    Wang XT; Li S; Zhang XB; Hou XP
    Yao Xue Xue Bao; 2003 Mar; 38(3):231-5. PubMed ID: 12830724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
    Danielyan K; Ding BS; Gottstein C; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2007 Jun; 321(3):947-52. PubMed ID: 17389242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator Composed of a Humanized Monoclonal Antibody against Activated Human Platelets and a Single-chain Urokinase.
    Liu ZH; Wan HY; Wang B; Li PX; Ru BG; Hu MH; Ruan CG
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 1998; 30(6):601-606. PubMed ID: 12167996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thrombolytic agents and strategies.
    Collen D; Lijnen HR
    Baillieres Clin Haematol; 1995 Jun; 8(2):425-35. PubMed ID: 7549072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.
    Kawano K; Aoki I; Aoki N; Homori M; Maki A; Hioki Y; Hasumura Y; Terano A; Arai T; Mizuno H; Ishikawa K
    Am Heart J; 1998 Feb; 135(2 Pt 1):268-71. PubMed ID: 9489975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
    Hunt JA; Petteway SR; Scuderi P; Novokhatny V
    Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential.
    Wirsching F; Luge C; Schwienhorst A
    Mol Genet Metab; 2002 Mar; 75(3):250-9. PubMed ID: 11914037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.